Biomarkers Help Predict Outcome in Deadly Lung Disease
By LabMedica International staff writers Posted on 15 Oct 2013 |
Image: Histopathology of idiopathic pulmonary fibrosis (Photo courtesy of the American Thoracic Society).
A gene expression profile has been identified that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF).
In most cases of IPF the cause cannot be identified, and there is no cure other than a lung transplant and while some patients experience a progressive course that leads to death within one to two years, others experience a relative stable disease.
Scientists from Yale University (New Haven, CT, USA) with colleagues from other institutions recruited a discovery cohort of 45 patients from the University of Chicago (IL, USA) and 75 patients in a replication cohort from the University of Pittsburgh (PA, USA). The goal of the study was to identify changes in expression of genes in the blood that are predictive of poor outcomes among patients with IPF.
The teams analyzed the expression of the genes in the whole genome of patients with IPF, using peripheral blood mononuclear cell (PBMC). They identified 52 genes that significantly correlated with outcome. They further found that the decreased expression of four genes that encode for cluster of differentiation 28 (CD28), inducible T-cell co-stimulator (ICOS), lymphocyte-specific protein tyrosine kinase (LCK), and interleukin 2 (IL2)-inducible T-cell kinase (ITK). These genes predicted shorter survival time in patients with IPF.
The investigators believe the discovery of these biomarkers will help physicians better predict disease presence, severity, and prognosis in IPF patients. Naftali Kaminski, MD, a professor at Yale School of Medicine and a senior author of the study said, “Given the fact that lung transplantation is the only therapy that has shown to improve survival in IPF, our test could allow physicians to refer IPF patients for lung transplant at the right time, not too late and not too early.”
The author concluded that microarray-derived 52-gene expression profile or quantitative reverse transcription polymerase chain reaction (qRT-PCR) of CD28, ICOS, LCK, and ITK members of this signature was sufficient to identify IPF patients destined for poor outcomes. Combining gene expression data with clinical parameters enhanced outcome prediction; thus, the results could have considerable value in clinical evaluations and management of patients with this devastating lung disease. The study was published on October 2, 2013, in the journal Science Translational Medicine.
Related Links:
Yale University
University of Chicago
University of Pittsburgh
In most cases of IPF the cause cannot be identified, and there is no cure other than a lung transplant and while some patients experience a progressive course that leads to death within one to two years, others experience a relative stable disease.
Scientists from Yale University (New Haven, CT, USA) with colleagues from other institutions recruited a discovery cohort of 45 patients from the University of Chicago (IL, USA) and 75 patients in a replication cohort from the University of Pittsburgh (PA, USA). The goal of the study was to identify changes in expression of genes in the blood that are predictive of poor outcomes among patients with IPF.
The teams analyzed the expression of the genes in the whole genome of patients with IPF, using peripheral blood mononuclear cell (PBMC). They identified 52 genes that significantly correlated with outcome. They further found that the decreased expression of four genes that encode for cluster of differentiation 28 (CD28), inducible T-cell co-stimulator (ICOS), lymphocyte-specific protein tyrosine kinase (LCK), and interleukin 2 (IL2)-inducible T-cell kinase (ITK). These genes predicted shorter survival time in patients with IPF.
The investigators believe the discovery of these biomarkers will help physicians better predict disease presence, severity, and prognosis in IPF patients. Naftali Kaminski, MD, a professor at Yale School of Medicine and a senior author of the study said, “Given the fact that lung transplantation is the only therapy that has shown to improve survival in IPF, our test could allow physicians to refer IPF patients for lung transplant at the right time, not too late and not too early.”
The author concluded that microarray-derived 52-gene expression profile or quantitative reverse transcription polymerase chain reaction (qRT-PCR) of CD28, ICOS, LCK, and ITK members of this signature was sufficient to identify IPF patients destined for poor outcomes. Combining gene expression data with clinical parameters enhanced outcome prediction; thus, the results could have considerable value in clinical evaluations and management of patients with this devastating lung disease. The study was published on October 2, 2013, in the journal Science Translational Medicine.
Related Links:
Yale University
University of Chicago
University of Pittsburgh
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear